References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Peer Reviewed
See detailCalcitonine dans la prévention secondaire et tertiaire de l’ostéoporose
Halkin, V; Reginster, Jean-Yves ULg

in Medi-Sphere (1999), 3

Detailed reference viewed: 12 (2 ULg)
Peer Reviewed
See detailAdvocado/soybean unsaponifiable mixture increased high molecular weight proteoglycans synthesis by human articular chondrocytes
Henrotin, Yves ULg; Labasse, A; Guillou, B et al

in Annals of Rheumatoid Arthritis (1999), 230

Detailed reference viewed: 18 (3 ULg)
Peer Reviewed
See detailThe use of different dual X-ray absorptiometry brands in a multicenter clinical trial
Slosman, DO; Provedini, DM; Meunier, PJ et al

in Journal of Clinical Densitometry : The Official Journal of the International Society for Clinical Densitometry (1999), 2

Detailed reference viewed: 18 (4 ULg)
Peer Reviewed
See detailL’utilisation du fluor dans la thérapeutique de l’ostéoporose
Reginster, Jean-Yves ULg

in Synoviale (1999), 81

Detailed reference viewed: 12 (4 ULg)
Peer Reviewed
See detailNew Therapeutic options
Reginster, Jean-Yves ULg; Henrotin, Yves ULg

in Bone Depeche (1999), 5

Detailed reference viewed: 11 (2 ULg)
Peer Reviewed
See detailBisphosphonates : an update
Reginster, Jean-Yves ULg

in Osteologia-Osteology (1999), 2

Detailed reference viewed: 10 (2 ULg)
Peer Reviewed
See detailReview of bone formation stimulants
Reginster, Jean-Yves ULg

in Osterologia-Osteology (1999), 2

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailTreatment of osteoporosis : where are we and where are we going to
Reginster, Jean-Yves ULg

in Morphologie : Bulletin de l'Association des Anatomistes (1999), 83(261), 41-5

In the past years, there has been a multiplication of drugs identified as candidates for use in the prevention or the treatment of osteoporosis. When treating established osteoporosis, the objective is to ... [more ▼]

In the past years, there has been a multiplication of drugs identified as candidates for use in the prevention or the treatment of osteoporosis. When treating established osteoporosis, the objective is to prevent further skeletal deterioration, improve bone mass and/or bone microarchitecture to provide a documented reduction of the risk of vertebral and/or peripheral fractures. Calcium and vitamin D have been shown to be particularly efficient in elderly patients, mainly to prevent non-vertebral fractures. By inhibiting osteoclastic activity, calcitonin improves bone mineral density at all sites. Preliminary results suggest that it might also decrease vertebral fracture rates. Bisphosphonates have been investigated for 20 years in the treatment of osteoporosis. Alendronate was shown to reduce spinal and extravertebral fractures. New formulations of fluoride, like monofluorophosphate appear to be particularly beneficial in women with mild to moderate osteoporosis. Several new compounds, including parathormone, strontium salts, ipriflavone or others are currently developed and subject to large investigational programs to demonstrate their ability to reduce fracture. [less ▲]

Detailed reference viewed: 9 (2 ULg)
Peer Reviewed
See detailEfficacy and safety of avocado soybean unsaponifiable (ASU)at two different daily doses in treatment of symptomatic osteoarthritis of the knee (KOA)
Appelboom, T; Reginster, Jean-Yves ULg; Schuermans, J et al

in Osteoarthritis and Cartilage (1999), 7(SA), 117

Detailed reference viewed: 13 (1 ULg)
Peer Reviewed
See detailIsokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrosis
Henrotin, Yves ULg; Croisier, Jean-Louis ULg; Dumont, R et al

in Osteoarthritis and Cartilage (1999), 7(SA), 94

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailIn vitro induced imbalance between stromelysin and TIMP-1 production by human chondrocytes
Henrotin, Yves ULg; Labasse, A; Crielaard, Jean-Michel ULg et al

in Osteoarthritis and Cartilage (1999), 7(SA), 33

Detailed reference viewed: 3 (1 ULg)
Peer Reviewed
See detailEffects of nimesulide and indomethacin on cyclooxygenaxse-1 and 2 : a comparative study
De Leval, X; Dogne, JM; Neven, P et al

in Osteoarthritis and Cartilage (1999), 7(SA), 32

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailRisedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density
Ribot, C; Smith, R; Fogelman, I et al

in Journal of Bone and Mineral Research (1999), 14(S1), 136

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailRisedronate significantly reduces vertebral and non-vertebral fractures in osteoporotic women
Roux, C; Keller, M; Eastell, R et al

in Journal of Bone and Mineral Research (1999), 14(S1), 538

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailSafety of strontium ranelate in prevention of postmenopausal bone loss - a double-blind, prospective, placebo-controlled study
Reginster, Jean-Yves ULg; Roux, C; Jupsin, I et al

in Journal of Bone and Mineral Research (1999), 14(S1), 412

Detailed reference viewed: 3 (1 ULg)
Peer Reviewed
See detailRisedronate is well-tolerated in women with osteoporosis
McClung, M; Eastell, R; Watts, N et al

in Journal of Bone and Mineral Research (1999), 14(S1), 538

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailCommunication strategy increases osteoporosis awareness in postmenopausal women
Tellier, V; De Maeseneer, J; Cartier, P et al

in Journal of Bone and Mineral Research (1999), 14(S1), 385

Detailed reference viewed: 3 (1 ULg)
Peer Reviewed
See detailRisedronate produces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass
Fogelman, I; Ribot, C; Smith, R et al

in Calcified Tissue International (1999), 64(S1), 69

Detailed reference viewed: 7 (2 ULg)
Peer Reviewed
See detailRaloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women
Delmas, PD; Ensrud, KE; Harris, S et al

in Calcified Tissue International (1999), 64(S1), 43

Detailed reference viewed: 7 (2 ULg)